Degradable biological microneedle patch and preparation method thereof

By preparing degradable biological microneedle patches, glutamate is delivered to hair follicles, and long-term treatment of androgenic hair loss is achieved, poor compliance with existing treatment methods and side effects, and safe and efficient treatment plans are provided .

CN118924672APending Publication Date: 2024-11-12ZHICHENG MEDICAL TECH (HUBEI) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410996913.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing androgenic hair loss (AGA) treatments have problems with poor drug compliance, side effects and high costs. Traditional drugs such as minoxidil solution are frequently administered and bioabsorbent, and hair transplant surgery is risky and expensive.

Method used

Degradable biological microneedle patches are used to prepare PDMS molds, filled with GA-PLGA mixed casting solution and vacuum treatment, and added hyaluronic acid to form HA group. After drying and curing, the microneedle is peeled off. The accuracy and permeability of the microneedle are used to Glutamate is delivered to hair follicles, achieving mechanical stimulation and sustained release.

Benefits of technology

Achieve long-term treatment of AGA, improves drug absorption rate, reduces drug delivery frequency, significantly improves hair loss symptoms, provides safe and non-invasive treatment options, improves the quality of life of patients, and the pathogenesis of androgen hair loss Provides a new research perspective.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924672A_ABST
    Figure CN118924672A_ABST
Patent Text Reader

Abstract

The invention discloses a degradable biological microneedle patch and a preparation method thereof, on the basis of water-soluble MNs prepared from hyaluronic acid (HA), mechanical stimulation is provided for the skin in the skin insertion process, the MNs are rapidly dissolved after being in contact with tissue fluid (ISF) under the skin, then a GA needle packaged by polylactic acid-polyglycolic acid (PLGA) is provided, and along with slow degradation of a PLGA needle, the degradable biological microneedle patch can be used for preparing a degradable biological microneedle patch. The loaded GA is gradually released, the microneedle is used as a substrate, the advantages of accuracy and permeability of the microneedle are fully utilized, the GA is delivered into hair follicles in an alopecia area, and continuous release of the GA in the hair follicles is achieved. The prepared microneedle for treating androgenetic alopecia has important value and significance in clinical, social and scientific aspects and the like, not only brings good news to patients, but also makes positive contributions to progress of medical technology and social development, and therefore, the microneedle has a good application prospect in treating androgenetic alopecia. It is necessary to further deeply research, popularize and apply the microneedle to treat androgen alopecia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a degradable biological microneedle patch and a preparation method thereof. Background Art

[0002] Hair loss is common in both men and women and is often caused by physiological or pathological conditions, such as medications, trauma, stress, and autoimmune diseases. In today's society, more than 50% of the general population suffers from hair loss. Several factors can affect hair health, including genetics, chemical exposure, lifestyle, smoking, medications, stress, infection, and menopause.

[0003] The most common form of hair loss is androgenetic alopecia (AGA), a chronic progressive disease caused by high levels of testosterone (androgen). Androgens can be converted to dihydrotestosterone (DHT) by 5α-reductase, which enters the cell nucleus and has a toxic effect on the cell, leading to apoptosis of keratinocytes in the hair follicles and hair loss. Its main feature is the gradual thinning and loss of hair.

[0004] AGA mainly affects men, but it can also affect women. According to statistics, more than half of men worldwide will experience varying degrees of androgenic alopecia by the age of 60. Generally speaking, the location and severity of hair loss in AGA vary. Usually, the hair loss area in men has a characteristic "horseshoe" pattern. Androgenic alopecia not only affects the individual's appearance, but may also cause patients to have greater psychological stress and decreased self-esteem.

[0005] Although androgenetic alopecia (AGA) is not a serious life-threatening disease, the changes in body and image caused by hair loss can seriously affect patients' psychological health and quality of life, making the development of effective AGA treatment strategies highly desirable. Despite numerous efforts to treat AGA, such as by reducing oxidative stress, regulating the microenvironment around hair follicles, activating dermal cells, or stimulating hair follicle stem cells. Currently, there are only two drugs approved by the US Food and Drug Administration (FDA) for the treatment of AGA, including oral finasteride and topical minoxidil (MXD), both of which require continuous daily administration for more than 6 months. Since oral finasteride often causes systemic toxicity, most patients prefer minoxidil (MXD) preparations for hair regrowth. However, these topical minoxidil (MXD) solutions or foams usually have poor patient compliance; the treatment effect is relatively limited due to the physical barrier formed by the stratum corneum of the skin, resulting in frequent administration and low bioabsorption. On the other hand, hair transplant surgery is a common surgical treatment, but the cost of the surgery is high and there are certain risks and complications. Summary of the invention

[0006] The invention discloses a degradable biological microneedle patch and a preparation method thereof, aiming to solve the technical problems raised in the background technology.

[0007] In order to achieve the above object, the present invention adopts the following technical solutions:

[0008] A method for preparing a degradable biological microneedle patch comprises the following steps:

[0009] (a) Preparation of PDMS mold: The polydimethylsiloxane (PDMS) material is precisely engraved using a carbon dioxide laser etching process to form a mold with the desired microneedle structure.

[0010] (b) Preparation of GA stock solution: Glutamic acid (GA) of different concentrations was dissolved in dimethyl sulfoxide (DMSO) solution, and GA was completely dissolved by stirring or shaking to prepare a uniform GA stock solution.

[0011] (c) Preparation of PLGA solution: poly(lactic acid-co-glycolic acid) (PLGA) is dissolved in dioxane, and the PLGA is completely dissolved by heating, stirring or shaking to form a uniform PLGA solution.

[0012] (d) Preparation of GA-PLGA mixed casting solution: The GA stock solution prepared in step (b) is added to the PLGA solution prepared in step (c), and the mixture is mixed evenly to obtain GA-PLGA mixed casting solutions containing different GA concentrations.

[0013] (e) Solution filling and vacuum treatment: The GA-PLGA mixed casting solution obtained in step (d) was filled into the PDMS mold prepared in step (a). In order to promote the solution to fully penetrate into each microneedle structure of the mold, a vacuum treatment of 0.08 MPa was used for 10 minutes.

[0014] (f) Creation of HA groups: In the mold containing the GA-PLGA mixed casting solution, hyaluronic acid (HA) solution is added. The HA solution will form an HA group at the shaft tip of the microneedle, enhancing the functionality of the microneedle.

[0015] (g) Drying and curing: The mold containing the solution was placed in a desiccator at room temperature for 24 hours to allow the GA-PLGA solution to solidify in the mold to form PLGA microneedles with GA and HA groups.

[0016] (h) Peeling of microneedles: The dried mold was gently peeled off from the PDMS mold to obtain complete GA MNs.

[0017] In a preferred embodiment, a biodegradable bio-microneedle patch is based on water-soluble MNs made of hyaluronic acid (HA), which provides mechanical stimulation to the skin during skin insertion, and dissolves rapidly after contacting interstitial fluid (ISF) under the skin, and then provides polylactic acid-polyglycolic acid (PLGA) encapsulated GA needles. As the PLGA needles slowly degrade, the loaded GA is gradually released. The present invention uses microneedles as a substrate, fully utilizing the advantages of its precision and permeability to deliver GA to the hair follicles in the hair loss area, so that GA can reach the site of action more quickly and effectively. At the same time, the present invention can achieve sustained release of GA in the hair follicles by mixing PLGA with GA.

[0018] The biodegradable bio-microneedle patch and the preparation method thereof provided by the present invention have the following technical effects:

[0019] 1. The microneedle (MNs) patch prepared by the present invention combines mechanical stimulation with continuously released GA to achieve long-term treatment of AGA. Compared with commercial topical GA formulations that usually need to be used every day, the microneedle patch shows similar or even better hair regeneration effects at a monthly or weekly dosing frequency. These encouraging results show that the long-acting GA MNs patch has great application potential in clinical hair loss treatment because it increases drug absorption and reduces the frequency of dosing.

[0020] 2. The microneedle (MNs) patch prepared in the present invention has good biocompatibility in vitro and is well tolerated in AGA mice without causing any skin inflammation or tissue damage.

[0021] 3. The microneedle treatment provided by the present invention provides patients with another effective option besides traditional drugs and surgery, especially for patients who cannot tolerate traditional treatment methods or have contraindications, it has become a new hope. Its non-invasive treatment method ensures the safety of the treatment process, reduces the risk of side effects, and significantly improves the symptoms of hair loss and improves the quality of life of patients. In addition, the microneedle treatment process is simple and fast, and recovery is rapid, which will not bring too much life and work burden to patients.

[0022] 4. The microneedle therapy provided by the present invention provides us with a new perspective to deeply understand the pathogenesis of androgenic alopecia. Through the study of the efficacy and mechanism of microneedle therapy, we can further reveal the pathogenesis of androgenic alopecia and provide a more scientific basis for the treatment of the disease.

[0023] 5. The treatment provided by the microneedles prepared in the present invention is a model of close integration of clinical practice and scientific research. It provides us with rich experimental data and clinical samples, and promotes the progress of scientific research.

[0024] 6. The microneedles prepared by the present invention involve innovations in medical technology and equipment, and also provide new ideas and methods for the development of medical technology, promoting the innovation and development of the entire medical industry. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 A diagram of factors that affect hair health and how drugs can promote hair regeneration.

[0026] Figure 2 This is a structural schematic diagram of a degradable biological microneedle patch and a preparation method thereof proposed in the present invention, and a GA release process.

[0027] Figure 3 This is the manufacturing process of the PDMS mold and GAMNs in the process of preparing the microneedle for treating androgenic alopecia in Example 1 of the present invention.

[0028] Figure 4 These are optical microscope images and scanning electron microscope images of the microneedle MNs patch for treating androgenic alopecia prepared in Example 1 of the present invention, A is an optical microscope image of GA MNs, and B is an electron microscope image of GA MNs.

[0029] Figure 5 The mechanical strength curve and GA load capacity curve of the GA MNs patch for treating androgenic alopecia in Example 2 of the present invention are shown.

[0030] Figure 6 This is a microscope image of the in vitro degradation of the biodegradable microneedle patch in Example 3 of the present invention.

[0031] Figure 7 This is the in vitro drug release performance curve of GA MNs in Example 3 of the present invention.

[0032] Figure 8 These are the results of cell viability evaluation after NIH3T3 and DPC cells were co-cultured with GA, pure MNs and GA MNs for 24 hours in Example 4 of the present invention.

[0033] Fig. 9 This is a microscopic image of the NIH3T3 scratch healing experiment results in Example 5 of the present invention.

[0034] Fig.10 is the relative migration rate of NIH3T3 cells in Example 5 of the present invention.

[0035] Fig.11 This is a microscopic image of the DPC scratch healing experiment results in Example 5 of the present invention.

[0036] Fig.12 This is a microscopic image of the DPC scratch healing experiment results in Example 5 of the present invention.

[0037] Fig.13 is the relative migration rate of DPC cells in Example 5 of the present invention.

[0038] Fig.14 Schematic diagram of the establishment of an AGA mouse model in Example 6 of the present invention and the treatment strategy in the established model.

[0039] Fig.15 The representative photos of hair regeneration in the AGA mouse group in Example 6 of the present invention include a control group (ie, untreated), GA solution injection, blank MNs patch group, GA MNs patch, and daily topical application of 5% MXD solution.

[0040] Fig.16 This is a scanning electron microscope image of the regenerated hair of the mouse on the 28th day after hair removal in Example 6 of the present invention.

[0041] Fig.17 This is the evaluation of the hair follicle growth cycle of different groups of AGA mice in Example 6 of the present invention.

[0042] Fig.18 This is the hematoxylin-eosin (H&E) staining of the skin of different groups of AGA mice after treatment in Example 6 of the present invention.

[0043] Fig.19 These are representative images of Ki67 in skin tissues of different groups in Example 6 of the present invention.

[0044] Fig. 20 This is a quantitative analysis of Ki67 positive cells in different groups of skin tissues in Example 6 of the present invention. DETAILED DESCRIPTION

[0045] The technical solutions in the embodiments of the present invention will be described clearly and completely below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments.

[0046] A biodegradable microneedle patch and a preparation method thereof, the preparation process is as follows Figure 3 The specific preparation steps are as follows:

[0047] (1) Preparation of PDMS mold

[0048] The polydimethylsiloxane (PDMS) material is precisely engraved using a carbon dioxide laser etching process to form a mold with the desired microneedle structure.

[0049] (2) Preparation of GA stock solution

[0050] Different concentrations of glutamic acid (GA) were dissolved in a 100 mg / mL dimethyl sulfoxide (DMSO) solution, and GA was completely dissolved by stirring or shaking to prepare a uniform GA stock solution.

[0051] (3) Preparation of PLGA solution

[0052] 0.6 g of poly(lactic-co-glycolic acid) (PLGA) was dissolved in 2 ml of dioxane, and the PLGA was completely dissolved by heating, stirring or shaking to form a uniform PLGA solution.

[0053] (4) Preparation of GA-PLGA mixed casting solution

[0054] The GA stock solution prepared in step (2) was added to the PLGA solution prepared in step (3), and the mixture was mixed evenly to obtain GA-PLGA mixed casting solutions containing different GA concentrations (3.25, 7.5, 15, 15 and 30 mg / mL).

[0055] (5) Solution filling and vacuum treatment

[0056] The GA-PLGA mixed casting solution obtained in step (4) was filled into the PDMS mold prepared in step (1). In order to promote the solution to fully penetrate into each microneedle structure of the mold, a vacuum treatment of 0.08 MPa was used for 10 minutes.

[0057] (6) Creation of HA base

[0058] In the mold containing the GA-PLGA mixed casting solution, add hyaluronic acid (HA) (300 mg / mL) solution. The HA solution will form an HA group at the tip of the microneedle shaft, enhancing the functionality of the microneedle.

[0059] (7) Drying and curing

[0060] The mold containing the solution was placed in a desiccator at room temperature for 24 hours to solidify the GA-PLGA solution in the mold to form PLGA microneedles with GA and HA groups.

[0061] (8) Microneedle peeling

[0062] The dried mold was gently peeled off from the PDMS mold to obtain intact GA MNs.

[0063] Example 2

[0064] The mechanical strength and drug loading content of the biodegradable microneedles for treating androgenic alopecia prepared in Example 1 are described.

[0065] The mechanical strength of MNs was characterized using a universal tensile testing machine. The mechanical properties of GA MNs were tested using a universal tensile testing machine (HAAKE PolyDrive R600, Xinsansi, Shenzhen, China). GA MNs containing the highest GA concentration were placed on the sample plate with the tip facing up. The force-displacement curve of GA MNs was obtained by applying a compressive force to the GA MNs at a speed of 0.5 mm / min until a maximum force of 80 N was reached.

[0066] Such as the force-displacement curve ( Figure 5 ), the force applied to GA MNs increases with displacement without an obvious transition point, indicating that GA MNs have sufficient mechanical strength to pierce the skin without breaking.

[0067] In order to determine the content of GA loaded in microneedle patches with different GA concentrations, the dialysis bag method was used for analysis. The microneedle patches encapsulating GA with different concentrations of PLGA were placed in an appropriate solvent (such as PBS buffer) to dissolve and release the drug (GA). Select an appropriate molecular weight cutoff dialysis bag and put the dissolved PLGA microneedle patch solution into the dialysis bag. Make sure the bag is well sealed to prevent leakage of the solution or contamination of the bag. Soak the dialysis bag containing the PLGA microneedle patch solution in an appropriate buffer (such as PBS) and gradually release the drug (GA) into the buffer through dialysis. Take samples regularly during the dialysis process and analyze the concentration of GA in the samples taken out. Use UV-visible absorption spectroscopy to determine the concentration of GA. Based on the data obtained from the sampling analysis, calculate the drug content at different PLGA microneedle patch concentrations, usually expressed as a percentage or the amount of drug loaded per unit mass (such as microneedle patch).

[0068] Drug loading analysis Figure 5 shown.

[0069] Example 3

[0070] The in vitro degradation and in vitro drug release properties of the microneedle patch for the treatment of androgenic alopecia were characterized by applying Nile red-loaded MNs patches on pork skin and observing with microscopy.

[0071] Nile red loaded MNs were inserted into fresh porcine skin by pressing with the thumb for 1 min, dissolving the HA base while leaving the biodegradable needle tips in the skin. Then, after being applied to the skin for 10 min, the back of the patch was removed. After removing the base, the skin with treated and detached needle tips was analyzed using an optical microscope (Olympus) to detect the detached needle tips remaining in the skin. Microscopic images within the skin further demonstrated that red fluorescent PLGA MNs can be effectively delivered to the skin via the MNs patch.

[0072] To evaluate the in vitro release of GA from MNs patches, PBS containing 25% (v / v) ethanol was used as the release medium to simulate the previously reported body fluid conditions. Specifically, one MNs patch was placed in a glass bottle containing 2 mL of release medium. The glass bottle was placed on a shaker and shaken at 150 rpm and 37°C. At the predetermined time point, 1 mL of the release medium was collected and replaced with 1 mL of fresh medium. The GA concentration in the collected samples was measured at λ520nm using a microplate reader (SpectraMax M5, Molecular Devices). The concentration of GA was determined by fitting the absorbance of the solution to the standard curve.

[0073] In vitro degradation of GA MNs loaded with Nile red attached to pig skin Figure 6 The in vitro release curve of GA in the MNs patch is shown in Figure 7 shown.

[0074] Example 4

[0075] The biocompatibility of the GA MNs for treating androgenic alopecia prepared in Example 1 was evaluated in NIH3T3 and DPCs cells.

[0076] NIH3T3 and DPC cells were cultured in DMEM medium supplemented with 10% (v / v) fetal bovine serum and 1% (v / v) penicillin-streptomycin, and cultured in a humidified atmosphere of 5% CO2 at 37°C.

[0077] Cell viability was assessed using a cell counting kit-8 (CCK-8). NIH3T3 and DPC cells were cultured in 96-well plates at a density of 1×104 cells per well using GA, pure MNs, and GA MNs solutions. The culture medium was then changed with 100 μL of new culture medium and 10 μL of CCK-8 solution. Subsequently, the cells were incubated at 37°C for one hour in a humidified atmosphere containing 5% CO2. Then, the optical density (OD) was measured at 450 nm using a microplate reader. Each sample was analyzed three times to ensure the validity of the experimental results.

[0078] like Figure 8 As shown, NIH3T3 and DPC cells were co-cultured with GA, pure MNs, and GA MNs for 24 h, respectively. Compared with the control group (normal culture medium), no significant cytotoxicity was observed in any of the experimental groups. GA MNs had excellent cell viability in NIH3T3 cells and better cell viability in DPC cells. NIH3T3 and DPC cells are essential in the hair follicle microenvironment. They significantly affect the proliferation, migration, and differentiation of surrounding cells and regulate the hair follicle cycle.

[0079] Example 5

[0080] The cell migration ability was evaluated using a scratch healing assay. NIH3T3 and DPC cells were seeded in culture medium and cultured in a humidified atmosphere of 37°C and 5% CO2. When NIH3T3 and DPC cells reached 80% confluence, one scratch was made in each well of a 12-well plate. A 200 μL pipette tip was used to scratch the cell monolayer. The cells were co-cultured in culture media with different treatments. The control group was cultured in basic culture medium (pure DMEM culture medium). The other groups were co-cultured in pure DMEM culture medium solutions containing GA, pure MNs, and GA MNs. Images of the scratch wounds were observed under a microscope at 0 and 24 h.

[0081] The effect of MNs on the migration of NIH3T3 and DPC cells was evaluated. In vitro migration experiments showed that GA, pure MNs, and GA MNs could promote cell migration, among which GA MNs had the fastest migration speed, and the scratch area was almost completely closed at 24 h ( Fig. 9 , 10 , 11, 12).

[0082] Example 6

[0083] The therapeutic effect of the biodegradable microneedle prepared in Example 1 on androgenic alopecia is described. To evaluate hair regeneration, about 1 cm2 (1 cm×1 cm) of the dorsal skin of 7-week-old C57BL / 6 mice was depilated using an animal electric hair clipper and depilatory cream (Kracie Co., Ltd., Japan).

[0084] To further investigate the long-term hair regeneration effect of GA MNs patch in vivo, the AGA animal model was established by topical administration (0.1 mL / cm2) of testosterone (0.5%, w / v) prepared in ethanol (50%, v / v) solution to mice for 28 consecutive days. The AGA mice were then randomly divided into five groups to receive: (1) no treatment; (2) blank MNs patch; (3) conventional needle injection of GA solution; (4) daily topical application of 5% MXD solution; (5) GA MNs patch ( Fig.13 ). Each treatment was performed simultaneously with testosterone on days 1, 4, 7, 10, 10, and 13 after hair removal. The MNs patch was pressed into the skin for 1 min, and the basal layer was removed after 10 min. For the positive control, 5% minoxidil (0.1 mL / cm2) was applied topically once a day until day 13. Digital images of hair and skin were taken. On day 28, the diameter and density of regenerated hair were evaluated using a Firefly trichoscope DE337T (Belmont, USA) after hair removal. Finally, the coverage of regenerated hair was measured using ImageJ. As Fig.14As shown, the control group that did not receive any treatment had no hair growth within 28 days. In contrast, hair regeneration in the skin was observed in the mouse groups that were treated for 14 days with injection of GA solution, daily topical application of MXD solution, and GA MNs patch, indicating that the AGA mouse model was successfully established and the use of transdermal long-acting GAMNs patch in AGA mice could promote hair regeneration.

[0085] Interestingly, AGA model mice treated with blank-MNs also regenerated new hair, which may be induced by the mechanical stimulation of MNs, but the quality of the regenerated hair coverage was poor, SEM ( Fig.15 ). The blank MNs patch induced significant hair regeneration in mice and showed similar effects to daily topical MXD solution in terms of regenerated hair coverage, hair density, and hair diameter. Notably, the GA MNs patch showed superior therapeutic effects on the above parameters compared with daily topical MXD solution. These results indicate that the GA MNs patch has a long-lasting therapeutic effect on hair regeneration with a lower drug dose and less frequent administration. In addition, the application of the GA MNs patch resulted in significantly earlier onset of skin pigmentation, a commonly used indicator for evaluating hair regeneration, than the daily topical MXD solution, further indicating that the long-acting GA MNs patch exhibits better performance in the treatment of AGA.

[0086] Changes in hair follicle length and skin thickness are usually associated with the hair cycle, and both usually increase during the hair growth phase; therefore, hair follicle length and skin thickness are two important indicators for evaluating hair regeneration. After different treatments of AGA mice, the mice were sacrificed, their skin was fixed with formaldehyde, and stained with hematoxylin and eosin (H&E) to identify the hair follicles under the skin, and the dermal thickness ( Fig.17 ). A small number of hair follicles in the untreated AGA mice atrophied, while a large number of regenerated hair follicles were visible in the GA MNs patch group, and the hair follicles were enlarged, indicating that they entered the growth phase ( Fig.16 ). Although the blank MNs patch and daily MXD solution groups showed similar results in terms of hair follicle length and dermal thickness, the GA MNs patch showed a significant increase in both parameters, indicating that it was more effective in promoting new hair growth.

[0087] The induction of hair follicle growth is always associated with rapid and abundant proliferation of cells. Therefore, we further investigated the expression of Ki-67, which is widely used as a marker of cell proliferation. Consistent with the results of hair follicle length, the GA MNs patch group had the highest expression of Ki-67 in the hair follicles, suggesting that the application of long-acting GA MNs patches promoted cell proliferation associated with hair follicle induction ( Fig.18 , 19 ). In addition, the GA MNs patch showed good biocompatibility and did not cause any obvious cytotoxicity.

[0088] Notably, GA MNs patch showed superior therapeutic effects on the above parameters compared with daily topical application of MXD solution. These results suggest that GA MNs patch has a long-lasting therapeutic effect on hair regrowth at low doses and low dosing frequency.

[0089] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims

1. A biodegradable biological microneedle patch, comprising a microneedle patch, characterized in that: The raw materials of the microneedle patch include PDMS mold, GA stock solution, PLGA solution, GA-PLGA mixed casting solution and HA base.

2. A method for preparing a degradable biological microneedle patch, applied to the degradable biological microneedle patch according to claim 1, characterized in that: The specific steps include: Step 1: Preparation of PDMS mold: Use carbon dioxide laser etching process to accurately carve polydimethylsiloxane (PDMS) material to form a mold with the desired microneedle structure; Step 2: Preparation of GA stock solution: Dissolve glutamic acid (GA) of different concentrations in dimethyl sulfoxide (DMSO) solution, and completely dissolve GA by stirring or shaking to prepare a uniform GA stock solution; Step 3: Preparation of PLGA solution: dissolving poly(lactic acid-co-glycolic acid) (PLGA) in dioxane, and completely dissolving PLGA by heating, stirring or shaking to form a uniform PLGA solution; Step 4: Preparation of GA-PLGA mixed casting solution: adding the GA stock solution prepared in step (b) to the PLGA solution prepared in step (c), mixing evenly, to obtain GA-PLGA mixed casting solutions containing different GA concentrations; Step 5: Solution filling and vacuum treatment: The GA-PLGA mixed casting solution obtained in step 4 is filled into the PDMS mold prepared in step 1. In order to promote the solution to fully penetrate into each microneedle structure of the mold, a vacuum treatment of 0.08 MPa is used for 10 minutes; Step 6: Creation of HA base: Add hyaluronic acid (HA) solution into the mold containing GA-PLGA mixed casting solution, and the HA solution will form HA base at the shaft tip of the microneedle; Step 7: Drying and curing: The mold containing the solution is placed in a dryer at room temperature for 24 hours to allow the GA-PLGA solution to solidify in the mold to form PLGA microneedles with GA and HA groups; Step 8: Peeling off the microneedles: Gently peel off the dried mold from the PDMS mold to obtain complete GA MNs.

3. The method for preparing a degradable biological microneedle patch according to claim 2, characterized in that: The GA MNs obtained in step 7 are stored in a desiccator at room temperature to maintain their stability and functionality until use.

4. The method for preparing a degradable biological microneedle patch according to claim 3, characterized in that: The polylactic acid-glycolic acid copolymer microneedles containing glutamic acid prepared by the above steps have a specific GA concentration and HA group, and can be used in the medical fields of drug delivery and skin treatment.

5. A degradable biological microneedle patch and a preparation method thereof according to claim 4, characterized in that: The polylactic acid-glycolic acid copolymer microneedles containing the model dye prepared by the above steps, in step 4, in addition to adding the GA stock solution, also add the model dye. The addition of the model dye can be used to study the permeability and distribution of the microneedles in the skin.

6. A degradable biological microneedle patch and a preparation method thereof according to claim 5, characterized in that: The polylactic acid-glycolic acid copolymer microneedle with model dye prepared by the above steps contains the model dye in addition to GA and HA groups, and can be used for research or teaching.